Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts is a research paper published in PLoS ONE (2020). On theSindex it has a DataRank of 0. It has been cited 49 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of General Medical Sciences
Grant: NIH T32GM113896 / STXMSTP
St. Baldrick's Foundation
Grant: St. Baldrick's Scholar
Turn it Gold Foundation
Grant: Direct Laboratory Support
National Institutes of Health
Grant: 3T32GM113896-03S1
South Texas Medical Scientist Training Program (STX-MSTP)
NIGMS NIH HHS
Grant: T32 GM113896
FWCI
3.45
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Additional file 1 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Additional file 3 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Additional file 3 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Additional file 2 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Additional file 2 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis